Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Genasense (oblimersen) / Genta

NCT00004862: Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Completed

filgrastim, oblimersen sodium, cytarabine, fludarabine phosphate

National Cancer Institute (NCI)

Leukemia

12/01

NCT00070083: Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Completed

US, Canada

oblimersen sodium, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate

British Columbia Cancer Agency, National Cancer Institute (NCI)

Lymphoma

NCT00060112: Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

Terminated

oblimersen sodium, augmerosen, G3139, G3139 bcl-2 antisense oligodeoxynucleotide, Genasense, gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, pharmacological study, pharmacological studies, laboratory biomarker analysis

National Cancer Institute (NCI)

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific

12/09

NCT00736450: Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Terminated

oblimersen sodium, augmerosen, G3139, G3139 bcl-2 antisense oligodeoxynucleotide, Genasense, rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, doxorubicin hydrochloride, ADM, ADR, Adria, Adriamycin PFS, Adriamycin RDF, vincristine sulfate, leurocristine sulfate, VCR, Vincasar PFS, prednisone, DeCortin, Deltra, biopsy, biopsies, microarray analysis, gene expression profiling, immunohistochemistry staining method, immunohistochemistry, gene expression analysis, cytogenetic analysis

University of Nebraska, National Cancer Institute (NCI), Genta Incorporated

Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma

10/12



	Diseases Companies Products Productz Mechanisms of Action Sites